A standard dose of lorazepam 2.5 mg was given i.v. to two groups of mothers: (a) before surgical induction of labour and (b) at the beginning of the second stage of labour. A group of non-pregnant women was studied as control. Plasma concentrations of lorazepam were measured by gas-liquid chromatography, in the mothers before delivery, and in the mother and neonate at delivery and 24 and 48 h thereafter. Concentrations at delivery in the neonates were similar to those in the mothers in group (a), but significantly less in group (b). Fetal concentration rarely exceeded that in the mother. Measurements after delivery indicated that the neonates were able to metabolize lorazepam at the same rate as the mothers. Of the 22 neonates studied only one had an Apgar score of less than 8 at 5 rain and this score was 10 at 10 min.
The use of parenteral analgesia during labour is a common and widespread practice, but it is well known that the pain and discomfort of labour has not only a physical component but also an emotional one. The fear of experiencing physical pain may cause considerable anxiety before and during the early stages of labour. The introduction of the benzodiazepine drugs with their soporific and anxiolytic properties led to the use of diazepam in conjunction with the more traditional analgesics. The aim was to abolish the mother's fear and anxiety about the pain of labour. An early study (Bepko, Lowe and Waxman, 1965) showed that parenteral diazepam markedly reduced apprehension and discomfort associated with labour and also the amount of parenteral analgesic required. Later studies by Flowers, Rudolph and Desmond (1969) and Niswander (1969) supported these findings. However, the babies of some of the mothers who received diazepam showed temporary hypoactivity and hypotonia. Other reports have confirmed these observations, especially if large doses of diazepam were given (Owen, Irani and Blair, 1972; McCarthy, O'Donnell and Robinson, 1973) .
Lorazepam is the o-chlorophenyl derivative of the main metabolite of diazepam and has been found to be useful as an oral, i.m. or i.v. premedicant (Dundee F , 1977) . It has good soporific, anxiolytic and amnesic properties. We have examined its use in obstetric practice.
PATIENTS AND METHODS
Three groups of patients were studied: a control group of 10 non-pregnant patients undergoing routine minor gynaecological procedures (premedicant group); 10 pregnant women undergoing surgical induction of labour, to whom the drug was given before the procedure (first stage group); 12 parturients to whom tie drug was given at the beginning of the second stage of labour (second stage group). All the pregnant mothers had an uncomplicated ante-natal history and were expected to undergo spontaneous vaginal delivery.
None of the patients was receiving any medication containing a benzodiazepine. Informed consent was obtained from each patient on the day before operation or labour except for a number of patients in the second stage group who gave consent during the first stage of labour, following admission to the labour ward. Patients in the first and second stage groups were comparable with respect to weight and height, as were the premedicant group, except that, as expected, the weights of this last group were less (table I) .
A standard dose of lorazepam 2.5 mg was given i.v. over a period of 15 s into a large forearm vein. This was considered to be near to the optimum dose to produce adequate sedation in adults.
Venous blood was sampled (5-10 ml) via a cannula and three-way tap from the contralateral forearm • Analysis was performed by gas-liquid chromatography following benzene extraction as described by Howard and others (1977) and modified by Howard and others (1978) for micro samples. All the samples for a particular patient and her baby were analysed on the same day by one operator using the same standard and column. The condition of the infant was assessed at 1 and 5 min after delivery using the 10-point Apgar score.
RESULTS
The mean plasma concentrations of lorazepam are shown in figure 1. The drug "decay profiles" are similar in the three groups. The only significant variation was between the premedicant and the first stage groups at 120 min after injection, where there was a difference between the means (P<0.05).
The injection-delivery times in the first stage group ranged from 180 to 447 min (mean 293). The neonatal mean plasma lorazepam concentration at delivery was not significantly different from that of the mothers (P>0.1) (table III; fig. 2 ). In the second stage group the injection-delivery time range was 5-67 min (mean 21) with nine of the 12 being within 20 min). In this group the neonatal mean plasma lorazepam concentration was significantly smaller (P< 0.005) than that of the mothers ( fig. 3) . Figure 4 shows the ratio of neonatal to maternal plasma lorazepam concentration at delivery. In the first stage group this value was in the range 0.85-1.33 ng ml" 1 (mean 1.04 + 0.05), whereas in the second stage group the range was 0.59-1.21 ng ml-1 (mean 0.76 + 0.05). Only when delivery occurred more than 240 min after injection was the neonatalmaternal ratio greater than unity.
The ability of the neonate to redistribute and metabolize the drug is of vital importance and the results show that the neonates of both groups were able to remove lorazepam from the plasma at the same rate as the mothers (figs 5,6). The mean plasma lorazepam concentrations at 24 and 48 h in the infants of the first stage group were 17.6 ± 1.30 and 13.4 ± 1.83 ng ml" 1 respectively, with the corresponding maternal means 17.0+ 1.79 and 12.5 ± 1.83 ' ng ml"
1 . The mean concentrations at 24 and 48 h in the infants of the second stage group were 13.25 ± 1.20 and 10.30+1.30 ng ml" 1 respectively and corresponding maternal concentrations at the same time intervals were 12.40 ±0.80 and 7.80 ± 1.20 ng ml-1 . The decrease in plasma lorazepam concentration in both mother and neonate in each group between the time of delivery and 24 h after delivery was highly significant (P< 0.001). The plasma lorazepam values at 24 and 48 h after delivery were very small and approached the lower limit of sensitivity of the method of detection.
The Apgar scores of the neonates and the plasma lorazepam concentrations at delivery are shown in table IV. All the scores were good except in two patients in the first stage group who appeared to have abnormalities of the fetal heart rate during second stage (Type II dips). One of these mothers had received pethidine 100 mg i.m. 22 min before delivery.
DISCUSSION
The pattern of plasma lorazepam concentrations in all three adult groups in this study was similar to those published by Elliott (1976) and Dundee and others (1978) , although our absolute values were smaller because of the dose used. Thus it would appear that the parturient was able to metabolize and excrete lorazepam at the same overall rate as a nonpregnant patient. The significant difference between the mean plasma concentrations of the premedicant group and the first stage group at 120 min may be attributed to the distribution of a standard dose of lorazepam throughout the significantly greater body mass of the pregnant patient (table I) . The neonatal (mixed cord) plasma concentrations were small in the second stage group even though the maternal plasma concentrations were large, but the injectiondelivery time was short. In the other group, despite delivery several hours after administration of i.v. lorazepam, the neonatal plasma concentrations were not greater than those of the mothers; by this time the plasma concentrations in the mother were small. There is no published comparison of plasma lorazepam concentrations with soporific action. However, Dundee and others (1979) found no drowsiness 24 h after premedication, with plasma concentrations of 21-50 ng ml" 1 . We conclude that concentrations of 30-40 ng ml"" 1 found at delivery in this study did not have a soporific action, although the anxiolytic action was still evident. The findings relating to the neonate at delivery are different from those produced by diazepam. Gamble and others (1977) found significantly greater diazepam concentrations in the neonates than in the mothers at delivery. Lorazepam does not appear to cross the placental barrier as readily as diazepam. Our plasma lorazepam neonate-maternal ratio was 0.59-1.21 (mean 0.76 ±0.05) for the second stage group and 0.85-1.33 (mean 1.05 ± 0.05) for the first stage group. Gamble and others (1977) reported a range for diazepam of about 0.8-2.6, with a noted increase if the diazepam injection-delivery time was more than lh.
The ability of a drug to cross cell membranes is influenced by degree of ionization, lipid solubility, molecular weight and concentration gradient. Lorazepam has a molecular weight (321.2) similar to that of diazepam (284.7). It has two pKa values-at 1.3 and 11.5 (Smith and Rawlins, 1973) -and therefore at blood pH it is largely in the un-ionized form. Little is known about the protein binding of lorazepam in the fetus or neonate, but it is thought that only between 70 and 80% is protein-bound in the adult However, it is obvious from our results that lorazepam does not cross the placenta rapidly and does not appear in great concentrations in plasma in the neonate. The neonate's lorazepam "load" at delivery was dealt with (metabolized or excreted) as rapidly as the mother's in both first and second stage groups (figs 5, 6) . Plasma concentrations in the neonate 24 h after delivery were similar to those of the respective mother. Metabolism of lorazepam is a one-stage process involving the production of a glucuronide, which itself has no pharmacological activity and is excreted easily. However, it is possible that metabolism might be retarded in the premature neonate with reduced enzymatic function in the liver. This result is different from that reported for diazepam; there remains a much greater plasma concentration of diazepam in the neonate 24 h after delivery (Gamble et al., 1977) . Diazepam is metabolized relatively easily by the neonate, but one of its metabolites, n-desmethyldiazepam, is pharmacologically active for a considerable time.
All the neonates studied thrived during their time in hospital and none was retained longer than normal for the degree of parity of the mother, except when breast feeding was being established. The two low Apgar scores in the first stage group could be attributed to obstetric complications and, in one case, to the administration of an analgesic near the time of delivery. 
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UN ESTUDIO DE CONCENTRACIONES PLASMATICAS DE LORAZEPAM EN MADRES Y NEONATOS
SUMARIO
Se administr6 una dosis standard de 2,5 mg de lorazepam a dos grupos de madres: (a) antes de la induccidn quirurgica del parto y (b) al principio de la segunda fase del parto. Se realizd el estudio de un grupo de mujeres no-embarazadas, como control. Se midieron por cromatografia gas-liquido las concentraciones de lorazepam en el plasma de las madres antes del parto y en madres y neonatos al momento del parto y 24 y 48 h despu£s. Al momento del parto, las concentraciones en los neonatos eran similares a las de las madres del grupo (a), pero mucho mas bajas en el grupo (b). Las concentraciones en los fetos raramente excedian de las de las madres. Las mediciones despu6s del parto demostraron que les neonatos podian metabolizar el lorazepam con la misma rapidez que sus madres. De los 22 neonatos estudiados, uno solo tenia un recuento de menos de 8 a 5 min, y de 10 a 10 min.
